Form 4: Revolution Medicines Exec Sells Shares for Tax Obligation

A Revolution Medicines executive sold 5,447 shares of common stock at $76.8172 per share to cover tax withholding obligations from RSU vesting.

Summary

• Stephen Michael Kelsey, President, Research and Development at Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved the disposition of 5,447 shares of common stock.
• The shares were sold at a price of $76.8172 per share.
• This sale was executed on December 16, 2025.
• The transaction was made pursuant to a Rule 10b5-1 plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following this transaction, Stephen Michael Kelsey beneficially owns 278,600 shares, which includes 73,576 restricted stock units.

Sentiment

Score: 5

Explanation: Neutral. This is a routine, pre-planned insider sale for tax purposes, which is common for executives receiving equity compensation. It does not indicate a positive or negative view on the company's future performance.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned sale for tax purposes rather than a discretionary sale based on new negative information.

Negatives

• The sale reduces the executive's direct common stock holdings, although it is for a specific tax purpose related to equity compensation.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This is a routine insider transaction for a biotechnology company. Such sales are common for executives to manage tax liabilities arising from equity compensation and do not typically reflect a change in the company's fundamental outlook or broader industry trends.

Related Party Transactions

• The filing reports a direct sale of common stock by Stephen Michael Kelsey, President, Research and Development, to satisfy tax withholding obligations related to RSU vesting. This is an insider transaction.

Stakeholder Impact

• Shareholders: A minor reduction in an executive's direct common stock holdings, but under a pre-planned tax-related sale, so minimal impact on investor sentiment.
• Employees, Customers, Suppliers, Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by an executive to cover tax obligations related to RSU vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's long-term prospects or new material information. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Revolution Medicines, RVMD, Stephen Michael Kelsey, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Restricted Stock Units, RSU, Tax Withholding, Biotechnology, Pharmaceuticals